This Study Tests Empagliflozin in Patients With Chronic Heart Failure With Preserved Ejection Fraction (HFpEF). The Study Looks at How Far Patients Can Walk in 6 Minutes and at Their Heart Failure Symptoms.
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 315 participants.
Also called NCT03448406
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 315 participants
- Registry
-
NCT03448406 -
2017-004072-59
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Australia, Canada, Germany, Greece, Italy, Norway, Poland, Portugal, Spain, Sweden
- Registry status
- Completed
Technical summary
Registry record NCT03448406. Randomized; double masking; primary purpose treatment. Start 2018-03-20 (actual); primary completion 2019-10-04 (actual). Results posted on 2020-12-08.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- This Study Tests Empagliflozin in Patients With Chronic Heart Failure With Preserved Ejection Fraction (HFpEF). The Study Looks at How Far Patients Can Walk in 6 Minutes and at Their Heart Failure Symptoms.
- Condition
- Heart Failure
- Intervention (Drug)
- Empagliflozin
- Intervention (Drug)
- Placebo
- Lead sponsor
- Boehringer Ingelheim
- Collaborator
- Eli Lilly and Company
Record details
- Record id
cardio:ct-nct03448406- Content hash
9f88c24c63bb09b0c04537eebe47dec104ca3f96a8f55239f08e5d9cfe340712